JPH0216285B2 - - Google Patents
Info
- Publication number
- JPH0216285B2 JPH0216285B2 JP18861081A JP18861081A JPH0216285B2 JP H0216285 B2 JPH0216285 B2 JP H0216285B2 JP 18861081 A JP18861081 A JP 18861081A JP 18861081 A JP18861081 A JP 18861081A JP H0216285 B2 JPH0216285 B2 JP H0216285B2
- Authority
- JP
- Japan
- Prior art keywords
- platonin
- rheumatoid arthritis
- effect
- day
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 20
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- -1 cyanine compound Chemical class 0.000 claims description 5
- RREURMKQENZDQR-UHFFFAOYSA-N trithiazole Chemical compound S1SC=NS1 RREURMKQENZDQR-UHFFFAOYSA-N 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- FKFUHAJJKUCVRF-UHFFFAOYSA-N 2-[3,5-bis(3-heptyl-4-methyl-1,3-thiazol-3-ium-2-yl)penta-2,4-dienylidene]-3-heptyl-4-methyl-1,3-thiazole Chemical compound CCCCCCCN1C(C)=CSC1=CC=C(C1=[N+](C(C)=CS1)CCCCCCC)C=CC1=[N+](CCCCCCC)C(C)=CS1 FKFUHAJJKUCVRF-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 208000009386 Experimental Arthritis Diseases 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 6
- 239000000679 carrageenan Substances 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 229940113118 carrageenan Drugs 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 239000002955 immunomodulating agent Substances 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229960001614 levamisole Drugs 0.000 description 6
- 229960001639 penicillamine Drugs 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QPJBONAWFAURGB-UHFFFAOYSA-L Lobenzarit disodium Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C([O-])=O QPJBONAWFAURGB-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Landscapes
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18861081A JPS5890510A (ja) | 1981-11-24 | 1981-11-24 | 慢性関節リウマチ治療剤 |
| US06/404,843 US4464383A (en) | 1981-11-24 | 1982-08-03 | Immunomodulator containing trithiazole pentamethine cyanine derivative |
| DE19823234711 DE3234711A1 (de) | 1981-11-24 | 1982-09-18 | Ein trithiazolpentamethincyaninderivat enthaltender immunomodulator |
| CH5540/82A CH650673A5 (de) | 1981-11-24 | 1982-09-20 | Ein trithiazolpentamethincyaninderivat enthaltendes pharmazeutisches mittel. |
| GB08227128A GB2116422B (en) | 1981-11-24 | 1982-09-23 | Immunomodulator containing trithiazole pentamethine cyanine derivative |
| BE0/209198A BE894635A (fr) | 1981-11-24 | 1982-10-07 | Nouveaux medicaments immunomodulateurs contenant un derive de trithiazole-pentamethylidene cyanine |
| FR8216813A FR2516793B1 (fr) | 1981-11-24 | 1982-10-07 | Nouveaux medicaments immunomodulateurs contenant un derive de trithiazolepentamethylidene-cyanine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18861081A JPS5890510A (ja) | 1981-11-24 | 1981-11-24 | 慢性関節リウマチ治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5890510A JPS5890510A (ja) | 1983-05-30 |
| JPH0216285B2 true JPH0216285B2 (enrdf_load_stackoverflow) | 1990-04-16 |
Family
ID=16226680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18861081A Granted JPS5890510A (ja) | 1981-11-24 | 1981-11-24 | 慢性関節リウマチ治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5890510A (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4580479B2 (ja) * | 1998-12-21 | 2010-11-10 | 株式会社林原生物化学研究所 | 抗ｈｉｖ感染症剤 |
| EP1155694A4 (en) | 1998-12-24 | 2004-06-02 | Hayashibara Biochem Lab | HIV INFECTION AGENTS AND METHOD FOR TREATING HIV INFECTION |
-
1981
- 1981-11-24 JP JP18861081A patent/JPS5890510A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5890510A (ja) | 1983-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cohen et al. | Protection against aspirin-induced antral and duodenal damage with enprostil: a double-blind endoscopic study | |
| JP4452255B2 (ja) | 炎症性疾患の処置用医薬の製造におけるガバ類縁体、たとえばガバペンチンの使用 | |
| JP2588109B2 (ja) | 鎮痛剤 | |
| Hesse et al. | Hypoglycaemia after propranolol in children | |
| EP0066918A1 (en) | Anti-inflammatory compositions exhibiting minimized gastric damage | |
| JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| US4387093A (en) | Arthritis treatment | |
| HU206633B (en) | Process for producing pharmaceutical compositions for treating arthritis containing somatostatine analogues or derivatives thereof | |
| AU666992B2 (en) | Pharmaceutical composition for preventing or treating arteriosclerosis | |
| JPH0475205B2 (enrdf_load_stackoverflow) | ||
| Hart et al. | Phenylbutazone and its derivatives | |
| JPH0216285B2 (enrdf_load_stackoverflow) | ||
| Girard | Ketotifen and bronchial hyperreactivity in asthmatic patients | |
| US4103026A (en) | Treatment of peripheral vascular disease by non-intraarterial administration of prostaglandin E1 | |
| NL8105635A (nl) | Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking. | |
| Livingston | Treatment of Epilepsy With Diphenylhydantoin Sodium: Dilantin® Sodium | |
| US4612303A (en) | Therapeutic and/or preventive agent for obstructive respiratory diseases | |
| JP2938579B2 (ja) | 消化管壁保護剤 | |
| JP2003026567A (ja) | 補酵素ｑを有効成分とする粘膜投与用組成物 | |
| CA1337972C (en) | Agent for treating hyperuricemia | |
| JPH0216727B2 (enrdf_load_stackoverflow) | ||
| Lo et al. | Synergistic effect of vitamin C and aspirin on gastric lesions in the rat | |
| JPH0796488B2 (ja) | 白髪黒化剤 | |
| Mackay et al. | Haematemesis during oral aminophylline treatment | |
| US4742076A (en) | Etodolac for lowering rheumatoid factor |